Laura Beauchamps and Ifeoma Udoh (Credit: Liz Highleyman)
Pre-exposure prophylaxis (PrEP) was a major topic at the 2015 National HIV Prevention Conference(NHPC) last week in Atlanta. A growing body of evidence continues to confirm that Truvada PrEP is highly effective for preventing HIV if taken regularly, both in clinical trials and in real-world clinical use. Yet uptake has been uneven, and researchers and front-line health workers are learning about barriers to PrEP implementation and scale-up for diverse population groups.
"The argument is over about PrEP," National Institute of Allergy and Infectious Diseases (NIAID) director Anthony Fauci said during his opening lecture. "If you take the drug, it works, not only in a clinical trial but in the field."
That message appears to finally be getting out to people at risk for HIV and their providers.
"We're now reaching a tipping point where clinicians are hearing that their colleagues are prescribing PrEP and maybe they could too," said Dawn Smith of the Centers for Disease Control and Prevention.
This excerpt was cross-posted with the permission of HIVandHepatitis.com. Read the full article.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy